Literature DB >> 1325737

Anti-myeloperoxidase autoantibodies in patients with necrotizing glomerular and alveolar capillaritis.

X Bosch1, E Mirapeix, J Font, R Cervera, M Ingelmo, M A Khamashta, L Revert, G R Hughes, A Urbano-Márquez.   

Abstract

We conducted a prospective study of 651 Mediterranean patients from Catalonia (Spain) with well-defined forms of systemic vasculitis, connective tissue diseases, and renal and pulmonary disorders to determine the prevalence and clinical value of antineutrophil cytoplasmic autoantibodies (ANCA) with myeloperoxidase (MPO) specificity (MPO-ANCA). ANCA were first tested by indirect immunofluorescence on ethanol-fixed neutrophils. When a positive result was obtained, then MPO-ANCA were identified by performing the immunofluorescence assay again on neutrophils from a voluntary donor known to have a complete and selective deficiency of MPO. This disorder was detected by automated flow cytochemistry with the Technicon system and was further verified by cytochemical and biochemical studies. We detected MPO-ANCA in 61 of 70 (87%) patients with a perinuclear pattern (p-ANCA), but in none of 25 with a cytoplasmic pattern (c-ANCA). These results were corroborated by enzyme-linked immunosorbent assay (ELISA) using human purified MPO as a substrate. On immunofluorescence microscopy, all patients with MPO-ANCA were found to have a typical and restrictive immunostaining pattern. In our study, while c-ANCA were mainly found in patients with biopsy-proven Wegener's granulomatosis, MPO-ANCA identified those with idiopathic and polyarteritis nodosa-associated necrotizing and crescentic glomerulonephritis. In addition, pulmonary hemorrhage with necrotizing alveolar capillaritis as the main morphologic substrate occurred frequently among patients with MPO-ANCA, including three affected by polyarteritis nodosa and three who had pulmonary hemorrhage as the only clinical finding. On the other hand, these antibodies could be also detected in 30% of patients with a proven diagnosis of anti-glomerular basement membrane (GBM) disease.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325737     DOI: 10.1016/s0272-6386(12)80695-0

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  6 in total

Review 1.  Clinical value of antineutrophil cytoplasmic antibodies.

Authors:  V Rus; B S Handwerger
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

2.  Monitoring with serum SP-A, SP-D, and KL-6 in a patient with interstitial pneumonia complicated with ANCA-associated glomerulonephritis.

Authors:  Fumihiko Takahashi; Eriko Miura; Kiyoko Shibukawa; Junko Chinda; Naoyuki Miyokawa; Chieko Imamoto; Kenjiro Kikuchi; Naoyuki Hasebe
Journal:  CEN Case Rep       Date:  2013-03-18

3.  AP-VAS 2012 case report: a case of myeloperoxidase antineutrophil cytoplasmic antibody-positive microscopic polyangiitis with rapidly progressive glomerulonephritis and hearing loss.

Authors:  Maki Tsukamoto; Seiichiro Shimizu; Megumi Koizumi; Nobuo Kitahara; Yoshihiro Ohtaki; Shigeyuki Aoki; Hiroshi Miyakawa
Journal:  CEN Case Rep       Date:  2013-01-30

Review 4.  Eye manifestations in patients with perinuclear antineutrophil cytoplasmic antibody-associated vasculitis: case series and literature review.

Authors:  Toshihiko Matsuo
Journal:  Jpn J Ophthalmol       Date:  2007-04-06       Impact factor: 2.447

Review 5.  Pulmonary renal syndrome in a child with coexistence of anti-neutrophil cytoplasmic antibodies and anti-glomerular basement membrane disease: case report and literature review.

Authors:  Radovan Bogdanović; Predrag Minić; Jasmina Marković-Lipkovski; Nataša Stajić; Nataša Savić; Milan Rodić
Journal:  BMC Nephrol       Date:  2013-03-22       Impact factor: 2.388

6.  Coexistence of Anti-Glomerular Basement Membrane Antibodies and Anti-Neutrophil Cytoplasmic Antibodies in a Child With Human Leukocyte Antigen Susceptibility and Detailed Antibody Description: A Case Report.

Authors:  Li-Jun Xie; Zhao Cui; Xiao-Yu Jia; Zhi Chen; Xiao-Rong Liu; Ming-Hui Zhao
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.